Biophysical Society 2020 Daily Schedule

10:30 am – 12:00 pm Bruker Corporation Using NMR (Nuclear Magnetic Resonance) and EPR (Electron Paramagnetic Resonance) in Biophysics Magnet Resonance offers many insights into how biological systems function. The two techniques shed light on the identity of species, dynamics, and structures of proteins, peptides, nucleotides, and lipids. The speakers will present an overview of these techniques and applica- tions for people who may be new to the field and wish to incorporate them in their studies. NMR has long been a valuable tool for the determination of structures, the study of dynamic processes and the investigation of interactions in biological molecules. To conduct these studies on larger molecules high- er magnetic fields are required. Bruker BioSpin has successfully installed a 1.1 GHz NMR system in a customer laboratory and the delivery of the first 1.2 GHz system is imminent. To complement the higher magnetic fields Bruker Biospin has also introduced several new probes for liquid and solid state NMR. NMR has recently been used successfully for the characterization of large proteins such as monoclonal antibodies. The statistical analysis of NMR spectra allows the detection of changes in the high order structure of these molecules. Another growing area is the use of 19F in bio-molecular NMR. Both the introduction of new accessories and method permit more widespread use of this nucleus in NMR studies. EPR detects unpaired electrons in free radicals and transition metal ions. One electron transfer reactions result in unpaired electrons. Examples of paramagnetic species encountered in biology are; ROS (Reactive Oxygen Species), RNS (Reactive Nitrogen Species), amino acid radicals such as tyrosine and tryptophan radicals, paramagnetic intermediates in photosynthesis, and metalloenzymes. In addition to these naturally occurring paramagnetic species, spin labels can be incorporated into a number of biomolecules via SDSL (Site Directed Spin Labeling). Applications and techniques are; motional dynamics of proteins, peptides, and nucleotides via linsehape analysis, accessibility studies in membrane proteins or peptides via saturation measurements, and distance measurements (2-8 nm) via DEER (Double Electron-Electron Resonance) to complement other structural methods such as X‑ray, NMR, CryoEM and FRET. Speakers Clemens Anklin, Vice President, NMR Applications & Training, Bruker Corporation Ralph Weber, EPR Applications Manager, Bruker Corporation

12:30 pm – 2:00 pm Nanion Technologies Beyond Ion Channels and Transporters: Snapshots of the State-of the-Art Solutions For almost two decades Nanion Technologies provides diverse solutions for electrophysiologists worldwide. We aim to successfully implement innovative technologies in the fields of ion channel automated electro- physiology, monitoring of cell viability and contraction, as well as elec- trogenic transporters, with our chip- and plate-based devices. Covering the needs for low, medium and high throughput assays our portfolio is well suited to advance research and screening projects. During this year’s symposium, five snapshots of successful wide-ranging applica- tions, assays and emerging technologies from our product portfolio will be presented. Our symposium will start with an introduction by Dr. Niels Fertig (CEO, Nanion) as a guide through the overall capabilities of Nanion´s technology portfolio. In continuation, we will welcome our speakers. Our first snapshot, presented by Prof. Dr. Jamie Vandenberg (Victor Chang Cardiac Research Institute) will be focusing on the high through- put automated patch clamp (APC) screening of missense variants in KCNH2 mutations, a well-established cause of sudden cardiac death, using the SyncroPatch 384PE. Prof. Vandenberg will present a high throughput functional assay his group developed in order to differenti- ate between benign and pathogenic variants in KCNH2 gene. Dr. Marc Rogers (Metrion Biosciences) will continue with a snapshot focusing on validation of a CardioExcyte 96 impedance-based phenotypic assay, that is able to reproduce the chronic effects of a range of clinical drugs that affect human iPSC cardiomyocyte contractility and viability by multiple and diverse mechanisms, including ion channel and ionic pump inhibi- tion, DNA intercalation, proteasome and tyrosine kinase inhibition, and myosin disruption. One of the newest Nanion´s releases, the FLEXcyte 96, will be highlighted in the snapshot presented by Dr. Matthias Gossmann (innoVitro). Dr Gossmann will introduce the important impact this technology has on cardiac research, as it offers the potential to scale-up mechanical testing of cardiac contractile behavior, matura- tion and drug screening towards medium-throughput analysed under true physiological conditions. Moving from cardiac physiology, Nathan Thomas (University of Wisconsin-Madison) will introduce a new application of SSM-based electrophysiology, in the field of ion coupled transporters. With a novel approach the transporter stoichiometry is investigated via rever- sal potential determination. During his snapshot, SURFE2R N1 data obtained on transporters from the small multidrug resistance (SMR) family, with the goal of providing a better understanding of underlying transport mechanisms, will be presented. Finally, Dr. Stephen Hess (Evotec) will introduce the use of APC platforms to support ion channel drug discovery, focusing on the Nav1.1 channels, which positive modulators could be useful in treating cognitive disor- ders, epilepsy, and neurodegenerative diseases. To find novel positive modulators of NaV1.1 channels. Dr. Hess screened over 150K small molecules using the SyncroPatch 384PE and found confirmed hits which could serve as excellent starting points for further MedChem optimiza- tion towards potential therapeutics. The Nanion team is delighted to welcome you to our lunch symposium! Speakers Jamie Vandenberg, Co-Deputy Director, Head of Cardiac Electrophysiology, The Victor Chang Cardiac Research Institute Marc Rogers, Director, CSO, Metrion Biosciences Matthias Gossmann, Innovitro (FLX), Co-Founder & CEO, Innovitro

Nathan Thomas, University of Wisconsin-Madison Stephen Hess, Research Leader-Ion Channels, Evotec

26